Rafivirumab, formerly known as CR57, represents a novel antibody designed for VEGF receptor 2 , VEGFR2. Its journey from early identification involved a substantial investment by Nektar , followed by https://rafivirumabrabiesprophyl693811.blog-gold.com/profile